Skip to main content Skip to main navigation menu Skip to site footer

The performance of various laboratory parameters to differentiate follicular thyroid carcinoma and follicular thyroid adenoma

  • Satriya Kelana ,
  • Dwi Hari Susilo ,
  • Sahudi ,


Abstract

Background: Thyroid cancer continues to be a problem all over the world, with the number of cases increasing year after year. We aimed to examine the association between various laboratory parameters and follicular-type thyroid nodules. We also examined the performance of several parameters to differentiate malignant and benign follicular thyroid lesions.

Methods: This is a retrospective cohort study to determine the association between various laboratory parameters and follicular-type thyroid nodules in Dr. Soetomo General Hospital, Surabaya.

Results: A total of 62 patients were examined. The NLR in the follicular carcinoma group was 2.26 ± 1.35, whereas the NLR in the adenoma group was 2.72 ± 0.74. The average lymphocyte in the follicular carcinoma group was significantly higher than the adenoma group, 2.20 ± 0.78 vs. 1.76 ± 0.82. With a cut-off value of 2.405, NLR had a 69.40% accuracy rate for diagnosing a follicular adenoma (sensitivity: 70%; specificity: 69.2%, PPV: 30.4%, NPV: 92.3%). Lymphocyte had an accuracy of 80.6% in detecting follicular carcinoma (cut-off: 1.625; sensitivity: 80.8%; specificity: 80.0%, PPV: 95.5%, NPV: 44.4%). With an accuracy of 72.6% (cut-off: 270.500; sensitivity: 71.2%; specificity: 80.0%, PPV: 94.9%, NPV: 34.8%), platelet value is a promising parameter for differentiating follicular cancer and adenoma. There was a significant relationship between NLR, lymphocyte, and platelet with follicular-type thyroid nodules (P < 0.05 for all).

Conclusion: NLR, lymphocytes, and platelets are potential biomarkers that can be used to differentiate follicular thyroid carcinoma and follicular thyroid adenoma.

Keywords: neutrophil-lymphocyte ratio thyroid nodule follicular type

References

  1. Olson E, Wintheiser G, Wolfe KM, Droessler J, Silberstein PT. Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013. Cureus. 2019;11(2):e4127. Published 2019 Feb 24. doi:10.7759/cureus.4127.
  2. World Health Organization. Indonesia Source GLOBOCAN 2018. Int Agency Res Cancer. 2019;256:1–2.
  3. Sembiring YE, Reksoprawiro S, Panuwun T. Correlation between p53 protein expressions in the incidence of metastasis in well-differentiated thyroid cancer. Folia Medica Indones. 2009;45(No. 3):193–203.
  4. Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on Fundamental Mechanisms of Thyroid Cancer. Front Endocrinol (Lausanne). 2020;11:102. Published 2020 Mar 13. doi:10.3389/fendo.2020.00102.
  5. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020.
  6. McHenry CR, Phitayakorn R. Follicular adenoma and carcinoma of the thyroid gland. Oncologist. 2011;16(5):585-593. doi:10.1634/theoncologist.2010-0405.
  7. Fnais N, Soobiah C, Al-Qahtani K, et al. Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. Hum Pathol. 2015;46(10):1443-1454. doi:10.1016/j.humpath.2015.06.001.
  8. Vargas-Salas S, Martínez JR, Urra S, et al. Genetic testing for indeterminate thyroid cytology: review and meta-analysis. Endocr Relat Cancer. 2018;25(3):R163-R177. doi:10.1530/ERC-17-0405.
  9. Kocer D, Karakukcu C, Karaman H, Gokay F, Bayram F. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders?. Asian Pac J Cancer Prev. 2015;16(9):3875-3879. doi:10.7314/apjcp.2015.16.9.3875.
  10. Zhang D, Tang J, Kong D, et al. Impact of Gender and Age on the Prognosis of Differentiated Thyroid Carcinoma: a Retrospective Analysis Based on SEER. Horm Cancer. 2018;9(5):361-370. doi:10.1007/s12672-018-0340-y.
  11. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18(1):1-7. doi:10.1007/s12022-007-0002-z.
  12. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504-508. doi:10.1038/clpt.2009.254.
  13. Cunha LL, Marcello MA, Ward LS. The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocr Relat Cancer. 2014;21(3):R85-R103. Published 2014 Apr 28. doi:10.1530/ERC-13-0431.
  14. Saputra, H. M., & Hakim, L. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Testicular Germ Cell Tumor (GCT). Folia Medica Indonesiana. 2022;58(1). p39–45. https://doi.org/10.20473/fmi.v58i1.32599.
  15. Lowsby R, Gomes C, Jarman I, et al. Neutrophil to lymphocyte count ratio as an early indicator of blood stream infection in the emergency department. Emerg Med J. 2015;32(7):531-534. doi:10.1136/emermed-2014-204071.
  16. Minerva B, Ali I, Tanggo EH, Danardono E. Neutrophil lymphocyte ratio and clinical response after neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil regiment in locally advanced breast cancer. Eurasian J Biosci. 2020;14(1):2473–8.
  17. Ito Y, Onoda N, Kihara M, Miya A, Miyauchi A. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Differentiated Thyroid Carcinoma Having Distant Metastasis: A Comparison With Thyroglobulin-doubling Rate and Tumor Volume-doubling Rate. In Vivo. 2021;35(2):1125-1132. doi:10.21873/invivo.12358.
  18. Gong W, Yang S, Yang X, Guo F. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. Clinics (Sao Paulo). 2016;71(6):311-314. doi:10.6061/clinics/2016(06)04.
  19. Manatakis DK, Tseleni-Balafouta S, Balalis D, Soulou VN, Korkolis DP, Sakorafas GH, et al. Association of Baseline Neutrophil-to-Lymphocyte Ratio with Clinicopathological Characteristics of Papillary Thyroid Carcinoma. Int J Endocrinol. 2017. p1-7. DOI: 10.1155/2017/8471235.
  20. Prabawa IPY, Bhargah A, Liwang F, Tandio D, Tandio A, Lestari AAW, Budiana IPG, Manuaba IBAP. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pacific Journal of Cancer Prevention. 2019;20(3):863-868. doi:10.31557/APJCP.2019.20.3.863.
  21. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95(5):2325-2333. doi:10.1210/jc.2009-2564.
  22. Miftahussurur M, Waskito LA, Syam AF, et al. Analysis of risks of gastric cancer by gastric mucosa among Indonesian ethnic groups. PLoS One. 2019;14(5):e0216670. Published 2019 May 9. doi:10.1371/journal.pone.0216670.
  23. El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150. Published 2021 Dec 1. doi:10.1038/s41523-021-00346-1.
  24. Bastid J, Bonnefoy N, Eliaou JF, Bensussan A. Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. Oncoimmunology. 2014;3:e28273. Published 2014 Mar 27. doi:10.4161/onci.28273.
  25. He JR, Shen GP, Ren ZF, et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck. 2012;34(12):1769-1776. doi:10.1002/hed.22008.
  26. Palacios-Acedo AL, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy. Front Immunol. 2019;10:1805. Published 2019 Jul 31. doi:10.3389/fimmu.2019.01805.

How to Cite

Kelana, S., Susilo, D. H., & Sahudi. (2022). The performance of various laboratory parameters to differentiate follicular thyroid carcinoma and follicular thyroid adenoma. Bali Medical Journal, 11(3), 1461–1467. https://doi.org/10.15562/bmj.v11i3.3521
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
0

Share